Assessing treatment outcomes in toenail onychomycosis clinical trials

American Journal of Clinical Dermatology

Volumn 5, Issue 3, 2004, Pages 145-152

  Werschler, W Philip ^a,d   Bondar, George ^b   Armstrong, David ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Spokane Dermatology Clinic   (United States)

^c Rosalind Franklin University of Medicine and Science Dr William M Scholl College of Podiatric Medicine   (United States)

^d 3M Pharmaceut and Dermik Labs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CICLOPIROX; ITRACONAZOLE; TERBINAFINE;

ABDOMINAL PAIN; CLINICAL TRIAL; COMPARATIVE STUDY; DERMATOPHYTE; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; FINGER NAIL; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; MYCOLOGY; MYCOSIS; NAIL; ONYCHOMYCOSIS; PARAMETER; PHYSICIAN; PRIORITY JOURNAL; REVIEW; STOMATOLOGY; TOE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CLINICAL TRIALS; FOOT DERMATOSES; HUMANS; ITRACONAZOLE; NAPHTHALENES; ONYCHOMYCOSIS; PYRIDONES; TREATMENT OUTCOME;

EID: 3142550709     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405030-00002     Document Type: Review

References (33)

1. Andre J, Achten G. Onychomycosis. Int J Dermatol 1987; 26: 481-90
2. Baran R, Hay RJ, Tosti A, et al. A new classification of onychomycosis. Br J Dermatol 1998; 139: 567-71
3. Haneke E, Roseeuw D. The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 1999; 38 Suppl. 2: 7-12
4. Werschler WP, Smith SA, Bondar GL. Treatment of onychomycosis in the elderly. Clin Geriatr 2002; 10: 19-24, 29-30
5. Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997; 87: 546-50
6. Tom CM, Kane MP. Management of toenail onychomycosis. Am J Health Syst Pharm 1999; 56: 865-71
7. Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43 (4 Suppl.): S57-69
8. Del Rosso JQ. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 1997; 97: 339-46
9. Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001; 145: 3-8
10. Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996; 23: 305-13
11. Trepanier EF, Amsden GW. Current issues in onychomycosis. Ann Pharmacother 1998; 32: 204-14
12. Weinberg JM, Koestenblatt EK. Comparison of diagnostic methods in the evaluation of onychomycosis. Dermatol Online J 2001; 7: 236
13. Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31 (3 Pt 2): S68-74
14. Daniel CR, Elewski BE. The diagnosis of nail fungus infection revisited. Arch Dermatol 2000; 136: 1162-4
15. Sorrentino A, Haber G, Solotoff S. Update on treatments for onychomycosis. Drug Topics 2000 Sep; Suppl.: 3-12
16. Lawry MA, Haneke E, Strobeck K, et al. Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 2000; 136: 1112-6
17. Elewski BE, Scher RK, Aly R, et al. Double-blind, randomized comparison of itraconazole capsules vs placebo in the treatment of toenail onychomycosis. Cutis 1997; 59: 217-20
18. Haneke E, Abeck D, Ring J. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Mycoses 1998; 41: 521-7
19. Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. J Am Podiatr Med Assoc 2001; 91: 127-31
20. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001; 44: 485-91
21. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43 (4 Suppl.): S70-80
22. Fleckman P. Basic science of the nail unit. In: Scher RK, Daniel III CR, editors. Nails: therapy, diagnosis, surgery. Philadelphia (PA): WB Saunders, 1990: 36-51
23. De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141: 15-20
24. Sporanox® [package insert]. Titusville (NJ): Janssen Pharmaceutica Products, L.P., 2001
25. Lamisil® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2001
26. Penlac™ nail lacquer [package insert]. Berwyn (PA): Dermik Laboratories, 2000
27. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 Suppl. 56: 1-4
28. De Doncker PR, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173-7
29. Havu V, Brandt H, Heikkila H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230-4
30. Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303-8
31. Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23: 259-62
32. Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600
33. Gupta AK. Management options in onychomycosis. Am J Med Sports 2000; 2: 117-8, 128